Research and Markets (http://www.researchandmarkets.com/research/06d116/the_outlook_for_ph) has announced the addition of the "The Outlook for Pharmaceuticals in Central Asia" report to their offering.
The Outlook for Pharmaceutical Markets in Asia is a unique collection of management reports from Espicom Business Intelligence. Each report provides individual and highly-detailed analysis of each market, looking at the key regulatory, political, economic and corporate developments in the wider context of market structure, service and access. The reports are available individually, or as a discounted collection, and prices include 4 completely updated reports sent quarterly, plus comprehensive report sent annually. There are over 60 markets covered in the worldwide series.
Executive Summary
4 Key Markets Covered! Bangladesh China India Pakistan
Highlights from the region
INDIA India is a country of extremes. The vast majority of the population is both rural and poor, although urban poverty is also a problem. Modern healthcare technology and western style pharmaceuticals are not even an issue for millions of people. On a national level, the Indian health system is ill-equipped to cope with the rising number of elderly and the changing disease patterns, with an average of just 0.7 hospital beds and 0.6 physicians per thousand population. India faces the continuing challenge of fighting infectious diseases like malaria, tuberculosis and leprosy alongside increases in lifestyle related problems faced by the developed world, such as cancer, cardiovascular disease and diabetes.
India has more US FDA approved laboratories than any other country outside the USA. A number of US companies already source pharmaceutical raw materials from India. In comparison with China, the wide use of English in commerce is mooted as an advantage to US companies, along with India's tradition as an exporting nation. India should prove to be a useful regional production base. Partnering an Indian company may also provide a good route to commercialisation in targeted markets such as Brazil or Russia, where Indian companies have an established presence. In addition, India has a large and varied patient base along with the necessary chemical and analytical skills at a comparatively low cost to make it an attractive base for clinical trials. R&D alliances are already being forged between multinationals and domestic companies.
CHINA Growing at a rate of around 8.5% per annum, China undoubtedly has one of the fastest expanding pharmaceutical markets in the world. The country has the largest population, officially estimated at over 1.3 billion in 2005, and one of the world's biggest economies, with GDP estimated at US$4.1 trillion in 2008. That said, the country is by no means an easy market to penetrate. Its sheer size means per capita incomes are very low. The opening of the Chinese market has seen the gap divide between rich and poor grow since the 1980s, and this is evident in the healthcare system in China; with minimal funding from the government, healthcare establishments rely on fees and the sale of medicines to survive. It comes to no surprise then, that the majority of China's advanced facilities and best trained staff are to be found in the larger, more affluent cities like Beijing, Shanghai, Guangzhou and Tianjin. The Chinese pharmaceutical industry tends to focus on the manufacture of cheap generics and copycat drugs and counterfeiting remains a problem. Imports of pharmaceuticals, particularly that of retail medicines, have been growing strongly in recently years, nearly doubling in the period 2002-2006, and this trend looks set to continue in the near future with strong fundamentals in place.